Harpreet Singh

FDA Approval Summary: Sotorasib for <i>KRAS G12C</i> -Mutated Metastatic NSCLC

Erica C. Nakajima, Nicole Drezner, Xiaoxue Li et al. · Clinical Cancer Research · 2021 · 305 citations · Full text

Medicine, Oncology, Pharmacology +13

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Jennifer Gao, Joyce Cheng, Erik Bloomquist et al. · The Lancet Oncology · 2019 · 297 citations

Medicine, Oncology, Pharmacology +17

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Hmwe Hmwe Kyu, A Bhoomadevi, Mohammad Amin Aalipour et al. · The Lancet · 2025 · 275 citations · Full text

Public Health, Demography, Population Health Sciences +17

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions

Diana Bradford, Erin Larkins, Sirisha L. Mushti et al. · Clinical Cancer Research · 2020 · 167 citations

Medicine, Oncology, Molecular Oncology +12

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Preeti Narayan, Christy Osgood, Harpreet Singh et al. · Clinical Cancer Research · 2021 · 164 citations · Full text

Medicine, Oncology, Pharmacology +17